VASO - positive confirm from Mayo Clinic in today's news:
Friday March 3, 5:20 am Eastern Time
Company Press Release
SOURCE: Vasomedical, Inc.
Mayo Clinic Physicians Confirm Positive Early Results With Enhanced External Counterpulsation
WESTBURY, N.Y., March 3 /PRNewswire/ -- Vasomedical, Inc. (Nasdaq: VASO - news) announced today that the Mayo Clinic, one of the most respected medical facilities in the world, has reported further on initial results with enhanced external counterpulsation (EECP©) therapy. Their positive experience was recently published as an interview in the Rochester Post-Bulletin and confirms several case studies reported at the AHA in November.
Gregory Barsness, M.D., Medical Director for the EECP therapy program at Mayo reported, ``Of the 21 patients who've tried the therapy since Mayo started using it a year ago, 20 of them have had positive results, some have improved dramatically. We are cautiously optimistic about the therapy, ...we have had dramatic responses, so we're enthusiastic and we're actively pursuing it.'
EECP therapy is a noninvasive outpatient treatment for the angina (chest pain) which often accompanies coronary artery disease. The therapy, which is covered by Medicare, is relatively new to the Mayo Clinic, but is in use at over 100 centers across the country.
Dr. Barsness further indicated that Mayo and other medical centers are studying EECP therapy to determine why the treatment works in so many patients. He pointed out that heart disease is a leading killer of both men and women; many heart disease patients do not qualify for common treatment methods and EECP therapy could turn out to be a big help for these patients.
Vasomedical, Inc. is primarily engaged in designing, manufacturing, marketing and supporting external counterpulsation systems based on the company's proprietary technology. EECP© is a registered trademark for Vasomedical's enhanced external counterpulsation system. This system is now in use at major medical centers, including the Mayo Clinic, the Ochsner Foundation Hospital and the Miami Heart Institute, as well as medical centers affiliated with Columbia University, the University of Pittsburgh, the University of California San Diego, the University of California San Francisco, and the University of Virginia. The company provides hospitals, clinics and private practices EECP© equipment, treatment guidance and a staff training and maintenance program to ensure optimal patient outcomes.
Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release words such as ``anticipate,' ``believe,' ``estimate,' ``expect' and ``intend' and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the impact of competitive products and pricing; capacity and supply constraints or difficulties; product development, commercialization or technological difficulties; the regulatory and trade environment; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to revise any forward-looking statements as a result of future events or developments. |
